Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Stassen

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
The Journal of Biological Chemistry|February 29, 2000
Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodiesA P Bijnens, A Gils, I Knockaert, et al.
Circulation|November 1, 1990
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis modelD Collen, M Dewerchin, H J Rapold, et al.
Thrombosis and Haemostasis|September 7, 1992
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis modelY Imura, J M Stassen, I Vreys, et al.
Thrombosis and Haemostasis|December 2, 1991
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activatorT Kurokawa, S Iwasa, A Kakinuma, et al.
Thrombosis and Haemostasis|October 28, 1987
Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activatorJ M Stassen, I Juhan-Vague, M C Alessi, et al.
Blood|May 1, 1992
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboonsY Imura, J M Stassen, T Kurokawa, et al.
Thrombosis and Haemostasis|February 12, 1991
Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism modelD Collen, H R Lijnen, I Vanlinthout, et al.
Journal of Molecular Biology|March 25, 2000
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivationH Nar, M Bauer, J M Stassen, et al.
Thrombosis and Haemostasis|February 12, 1998
Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamsterH Yamamoto, I Vreys, J M Stassen, et al.
Thrombosis and Haemostasis|February 12, 1998
Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal modelF Stockmans, W Deberdt, A Nyström, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
The Journal of Biological Chemistry|February 29, 2000
Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodiesA P Bijnens, A Gils, I Knockaert, et al.
Circulation|November 1, 1990
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis modelD Collen, M Dewerchin, H J Rapold, et al.
Thrombosis and Haemostasis|September 7, 1992
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis modelY Imura, J M Stassen, I Vreys, et al.
Thrombosis and Haemostasis|December 2, 1991
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activatorT Kurokawa, S Iwasa, A Kakinuma, et al.
Thrombosis and Haemostasis|October 28, 1987
Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activatorJ M Stassen, I Juhan-Vague, M C Alessi, et al.
Blood|May 1, 1992
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboonsY Imura, J M Stassen, T Kurokawa, et al.
Thrombosis and Haemostasis|February 12, 1991
Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism modelD Collen, H R Lijnen, I Vanlinthout, et al.
Journal of Molecular Biology|March 25, 2000
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivationH Nar, M Bauer, J M Stassen, et al.
Thrombosis and Haemostasis|February 12, 1998
Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamsterH Yamamoto, I Vreys, J M Stassen, et al.
Thrombosis and Haemostasis|February 12, 1998
Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal modelF Stockmans, W Deberdt, A Nyström, et al.
Pageof 9